Endogenous morphogens and fibrin bioscaffolds for stem cell therapeutics

Trends in Biotechnology

Volumn 31, Issue 6, 2013, Pages 364-374

  Anitua, Eduardo ^a   Prado, Roberto ^a   Orive, Gorka ^a  

^a Foundation Eduardo Anitua   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3-D ENVIRONMENTS; CLINICAL TRANSLATION; ENDOGENOUS GROWTH; EX VIVO EXPANSION; FETAL BOVINE SERUM; MESENCHYMAL STEM CELL; PLATELET RICH PLASMA; STATE OF THE ART;

CELL CULTURE; FLOWCHARTING; STEM CELLS; TISSUE;

SCAFFOLDS (BIOLOGY);

BIOMATERIAL; FIBRIN; MORPHOGEN;

CELL CULTURE; CRYOPRESERVATION; EX VIVO STUDY; EXTRACELLULAR MATRIX; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING;

CELL CULTURE TECHNIQUES; FIBRIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PLASMA; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE SCAFFOLDS;

BOVINAE;

EID: 84878133042     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.04.003     Document Type: Review

References (98)

1. Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng. 2010, 12:87-117.
2. Giordano A., et al. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 2007, 211:27-35.
3. Bieback K., et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfus Med. Hemother. 2008, 35:286-294.
4. Kinzebach S., Bieback K. Expansion of mesenchymal stem/stromal cells under xenogenic-free culture conditions. Adv. Biochem. Eng. Biotechnol. 2013, 129:33-57.
5. Sensebe L., et al. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum. Gene Ther. 2011, 22:19-26.
6. Coelho M.B., et al. Intraoperative stem cell therapy. Annu. Rev. Biomed. Eng. 2012, 14:325-349.
7. Rauch C., et al. Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX 2011, 28:305-316.
8. Mannello F., Tonti G.A. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!. Stem Cells 2007, 25:1603-1609.
9. Tekkatte C., et al. 'Humanized' stem cell culture techniques: the animal serum controversy. Stem Cells Int. 2011, 2011:504723.
10. Anitua E., et al. Platelet-rich plasma: preparation and formulation. Oper. Tech. Ortho. 2012, 22:25-32.
11. Liu Y., et al. Injectable tissue-engineered bone composed of human adipose-derived stromal cells and platelet-rich plasma. Biomaterials 2008, 29:3338-3345.
12. Diesen D.L., Lawson J.H. Bovine thrombin: history, use, and risk in the surgical patient. Vascular 2008, 16(Suppl. 1):S29-S36.
13. Rodrigues M., et al. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res. Ther. 2010, 1:32.
14. Anitua E., et al. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006, 24:227-234.
15. Anitua E., et al. High-throughput proteomic characterization of plasma rich in growth factors (PRGF-Endoret)-derived fibrin clot interactome. J. Tissue Eng. Regen. Med. 2013, 10.1002/term.1721.
16. Anitua E., et al. Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J. Control Release 2012, 157:29-38.
17. Rodríguez-Jiménez F.J., et al. Platelet-rich plasma favors proliferation of canine adipose-derived mesenchymal stem cells in methacrylate-endcapped caprolactone porous scaffold niches. J. Funct. Biomater. 2012, 3:556-568.
18. Behnia H., et al. Repair of alveolar cleft defect with mesenchymal stem cells and platelet derived growth factors: a preliminary report. J. Craniomaxillofac. Surg. 2012, 40:2-7.
19. Oliva A., et al. Ex vivo expansion of bone marrow stromal cells by platelet-rich plasma: a promising strategy in maxillo-facial surgery. Int. J. Immunopathol. Pharmacol. 2005, 18:47-53.
20. Bernardo M.E., et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J. Cell. Physiol. 2007, 211:121-130.
21. Reinisch A., et al. Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen. Med. 2007, 2:371-382.
22. Coquelin L., et al. In vivo and in vitro comparison of three different allografts vitalized with human mesenchymal stromal cells. Tissue Eng. A 2012, 18:1921-1931.
23. Chevallier N., et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials 2010, 31:270-278.
24. Schallmoser K., Strunk D. Generation of a pool of human platelet lysate and efficient use in cell culture. Methods Mol. Biol. 2013, 946:349-362.
25. Greiner J.F., et al. Efficient animal-serum free 3D cultivation method for adult human neural crest-derived stem cell therapeutics. Eur. Cell Mater. 2011, 22:403-419.
26. Villa-Diaz L.G., et al. Concise review: the evolution of human pluripotent stem cell culture: from feeder cells to synthetic coatings. Stem Cells 2013, 31:1-7.
27. Lewis F., et al. A feeder-free, human plasma-derived hydrogel for maintenance of a human embryonic stem cell phenotype in vitro. Cell Regen. 2012, 1:6.
28. Shin S.H., et al. Enhanced cellular responses of human bone marrow stromal cells cultured on pretreated surface with allogenic platelet-rich plasma. Connect. Tissue Res. 2012, 53:318-326.
29. Shichinohe H., et al. Biological features of human bone marrow stromal cells (hBMSC) cultured with animal protein-free medium - safety and efficacy of clinical use for neurotransplantation. Transl. Stroke Res. 2011, 2:307-315.
30. Perez-Ilzarbe M., et al. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion (Paris) 2009, 49:1901-1910.
31. Schallmoser K., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion (Paris) 2007, 47:1436-1446.
32. Ben Azouna N., et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res. Ther. 2012, 3:6.
33. Bieback K., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
34. Doucet C., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J. Cell. Physiol. 2005, 205:228-236.
35. Flemming A., et al. Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J. Clin. Immunol. 2011, 31:1143-1156.
36. Naaijkens B.A., et al. Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res. 2012, 348:119-130.
37. Crespo-Diaz R., et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant. 2011, 20:797-811.
38. Tarte K., et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood 2010, 115:1549-1553.
39. Schallmoser K., et al. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica 2010, 95:867-874.
40. Abdelrazik H., et al. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur. J. Immunol. 2011, 41:3281-3290.
41. Fukaya Y., et al. Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an in vitro culture system. Exp. Mol. Med. 2012, 44:330-339.
42. Nold P., et al. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem. Biophys. Res. Commun. 2013, 430:325-330.
43. Wiehe J.M., et al. GMP-adapted overexpression of CXCR4 in human mesenchymal stem cells for cardiac repair. Int. J. Cardiol. 2012, 10.1016/j.ijcard.2012.05.065.
44. Murphy M.B., et al. Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials 2012, 33:5308-5316.
45. Nie H., et al. Musculoskeletal tissue engineering by endogenous stem/progenitor cells. Cell Tissue Res. 2012, 347:665-676.
46. Bhang S.H., et al. Platelet-rich plasma enhances the dermal regeneration efficacy of human adipose-derived stromal cells administered to skin wounds. Cell Transplant. 2013, 22:437-445.
47. Vaquero J., et al. Cell therapy with bone marrow stromal cells after intracerebral hemorrhage: impact of platelet-rich plasma scaffolds. Cytotherapy 2013, 15:33-43.
48. Jiang Z-q., et al. Repair of calvarial defects in rabbits with platelet-rich plasma as the scaffold for carrying bone marrow stromal cells. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2012, 113:327-333.
49. Gessmann J., et al. Plasma clots gelled by different amounts of calcium for stem cell delivery. Langenbecks Arch. Surg. 2013, 398:161-167.
50. Bryan N., et al. Derivation and performance of an entirely autologous injectable hydrogel delivery system for cell-based therapies. Biomaterials 2009, 30:180-188.
51. Zurita M., et al. Cell therapy for spinal cord repair: optimization of biologic scaffolds for survival and neural differentiation of human bone marrow stromal cells. Cytotherapy 2010, 12:522-537.
52. Centeno C.J., et al. Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med. Hypotheses 2008, 71:900-908.
53. Centeno C.J., et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician 2008, 11:343-353.
54. Koh Y.G., Choi Y.J. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee 2012, 19:902-907.
55. Giannini S., et al. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. Clin. Orthop. Relat. Res. 2009, 467:3307-3320.
56. Haleem A.M., et al. The Clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage 2010, 1:253-261.
57. Moroz A., et al. Platelet lysate 3D scaffold supports mesenchymal stem cell chondrogenesis: an improved approach in cartilage tissue engineering. Platelets 2012, 24:219-225.
58. Xie X., et al. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Biomaterials 2012, 33:7008-7018.
59. Gentile P., et al. A comparative translational study: the combined use of enhanced stromal vascular fraction and platelet-rich plasma improves fat grafting maintenance in breast reconstruction. Stem Cells Transl. Med. 2012, 1:341-351.
60. Cervelli V., et al. Platelet-rich plasma greatly potentiates insulin-induced adipogenic differentiation of human adipose-derived stem cells through a serine/threonine kinase Akt-dependent mechanism and promotes clinical fat graft maintenance. Stem Cells Transl. Med. 2012, 1:206-220.
61. Cervelli V., et al. Tissue regeneration in loss of substance on the lower limbs through use of platelet-rich plasma, stem cells from adipose tissue, and hyaluronic acid. Adv. Skin Wound Care 2010, 23:262-272.
62. Zhu X., et al. Transplantation of dental pulp stem cells and platelet-rich plasma for pulp regeneration. J. Endod. 2012, 38:1604-1609.
63. Iacono E., et al. Effects of mesenchymal stem cells isolated from amniotic fluid and platelet-rich plasma gel on severe decubitus ulcers in a septic neonatal foal. Res. Vet. Sci. 2012, 93:1439-1440.
64. Warnke P.H., et al. A clinically-feasible protocol for using human platelet lysate and mesenchymal stem cells in regenerative therapies. J. Craniomaxillofac. Surg. 2013, 41:153-161.
65. Salvade A., et al. Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng. C: Methods 2010, 16:201-214.
66. Chen B., et al. The effects of human platelet lysate on dental pulp stem cells derived from impacted human third molars. Biomaterials 2012, 33:5023-5035.
67. Behnia H., et al. Bone regeneration with a combination of nanocrystalline hydroxyapatite silica gel, platelet-rich growth factor, and mesenchymal stem cells: a histologic study in rabbit calvaria. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 115:e7-e15.
68. Kocaoemer A., et al. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
69. Del Bue M., et al. Equine adipose-tissue derived mesenchymal stem cells and platelet concentrates: their association in vitro and in vivo. Vet. Res. Commun. 2008, 32(Suppl. 1):S51-S55.
70. Kitoh H., et al. Differential effects of culture-expanded bone marrow cells on the regeneration of bone between the femoral and the tibial lengthenings. J. Pediatr. Orthop. 2009, 29:643-649.
71. Cecchetti L., et al. Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events. Blood 2011, 118:1903-1911.
72. Anitua E., et al. The type of platelet-rich plasma may influence the safety of the approach. Knee Surg. Sports Traumatol. Arthrosc. 2012, 10.1007/s00167-012-2043-1.
73. Fekete N., et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554.
74. Lohmann M., et al. Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS ONE 2012, 7:e37839.
75. Cho H.S., et al. Individual variation in growth factor concentrations in platelet-rich plasma and its influence on human mesenchymal stem cells. Korean J. Lab. Med. 2011, 31:212-218.
76. Lu P., et al. Long-distance growth and connectivity of neural stem cells after severe spinal cord injury. Cell 2012, 150:1264-1273.
77. Ferreira M.S., et al. Cord blood-hematopoietic stem cell expansion in 3D fibrin scaffolds with stromal support. Biomaterials 2012, 33:6987-6997.
78. Filho Cerruti H., et al. Allogenous bone grafts improved by bone marrow stem cells and platelet growth factors: clinical case reports. Artif. Organs 2007, 31:268-273.
79. Brodke D., et al. Bone grafts prepared with selective cell retention technology heal canine segmental defects as effectively as autograft. J. Orthop. Res. 2006, 24:857-866.
80. Chatterjea A., et al. Engineering new bone via a minimally invasive route using human bone marrow-derived stromal cell aggregates, microceramic particles, and human platelet-rich plasma gel. Tissue Eng. A 2013, 19:340-349.
81. Prins H.J., et al. Bone-forming capacity of mesenchymal stromal cells when cultured in the presence of human platelet lysate as substitute for fetal bovine serum. Tissue Eng. A 2009, 15:3741-3751.
82. Xue G., et al. Intravenous umbilical cord mesenchymal stem cell infusion for the treatment of combined malnutrition nonunion of the humerus and radial nerve injury. Regen. Med. 2011, 6:733-741.
83. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. J. Med. Case Rep. 2011, 5:296.
84. Sugiyama T., et al. Therapeutic impact of human bone marrow stromal cells expanded by animal serum-free medium for cerebral infarct in rats. Neurosurgery 2011, 68:1733-1742.
85. Ito M., et al. Validity of bone marrow stromal cell expansion by animal serum-free medium for cell transplantation therapy of cerebral infarct in rats - a serial MRI study. Transl. Stroke Res. 2011, 2:294-306.
86. Kitoh H., et al. Transplantation of culture expanded bone marrow cells and platelet rich plasma in distraction osteogenesis of the long bones. Bone 2007, 40:522-528.
87. Kitoh H., et al. Distraction osteogenesis of the lower extremity in patients with achondroplasia/hypochondroplasia treated with transplantation of culture-expanded bone marrow cells and platelet-rich plasma. J. Pediatr. Orthop. 2007, 27:629-634.
88. Kitoh H., et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis - a preliminary result of three cases. Bone 2004, 35:892-898.
89. Yamada Y., et al. Injectable tissue-engineered bone using autogenous bone marrow-derived stromal cells for maxillary sinus augmentation: clinical application report from a 2-6-year follow-up. Tissue Eng. A 2008, 14:1699-1707.
90. Yamada Y., et al. Osteotome technique with injectable tissue-engineered bone and simultaneous implant placement by cell therapy. Clin. Oral Implants Res. 2013, 24:468-474.
91. Yamada Y., et al. Injectable bone tissue engineering using expanded mesenchymal stem cells. Stem Cells 2013, 31:572-580.
92. Cheng K., et al. Transplantation of platelet gel spiked with cardiosphere-derived cells boosts structural and functional benefits relative to gel transplantation alone in rats with myocardial infarction. Biomaterials 2012, 33:2872-2879.
93. Behfar A., et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J. Am. Coll. Cardiol. 2010, 56:721-734.
94. Mifune Y., et al. The effect of platelet-rich plasma on the regenerative therapy of muscle derived stem cells for articular cartilage repair. Osteoarthritis Cartilage 2013, 21:175-185.
95. von Bonin M., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009, 43:245-251.
96. Lucchini G., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol. Blood Marrow Transplant. 2010, 16:1293-1301.
97. Reinisch A., et al. Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. Blood 2009, 113:6716-6725.
98. Blanton M.W., et al. Adipose stromal cells and platelet-rich plasma therapies synergistically increase revascularization during wound healing. Plast. Reconstr. Surg. 2009, 123:56S-64S.